NMD4C Website Updates: Resource & Training Hubs
We’re excited to share some updates to the NMD4C website!
We’ve created two hubs, the Resource Hub and the Training Hub to make it easier for all our members to find e-learning tools, and research resources:
- Training Hub: Our Training Hub brings together our learning platforms in one easy-to-find place. Here, you can access:
- LearNMD: Neuromuscular webinars for clinicians and researchers,
- imPORTND: Neuromuscular patient-oriented research training modules for researchers and patient partners and
- Train(e)d: Outcome measure training modules for clinical evaluators.
- Resource Hub: Our Resource Hub collects a variety of open-access databases for the Canadian NMD research community, including Canadian Biobanks, Fellowship Programs, Clinical Trials, Patient Oriented Research Resources, and Standard Operating Procedures (SOPs).
These resources are here to help advance research, encourage collaboration, and improve care for people living with NMDs across Canada.
Access Training Hub
Access Resource Hub
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.